ClinicalTrials.Veeva

Menu
F

Fremantle Dermatology | Fremantle, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Metvix
PEP005
Risankizumab
Secukinumab
LY3041658
JNJ-64304500
APD334
CNTO 1959
Tildrakizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 36 total trials

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib
Locations recently updated

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Active, not recruiting
Chronic Plaque Psoriasis
Moderate to Severe Nail Psoriasis
Drug: Placebo
Drug: Tildrakizumab

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

AbbVie logo
Lilly logo
Amgen logo
A
D
Galderma logo
Janssen (J&J Innovative Medicine) logo
P
A
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems